Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A revision of the 2000 British Association for Psychopharmacology evidence-based guidelines for treating depressive disorders with antidepressants was undertaken to incorporate new evidence and to update the recommendations where appropriate. A consensus meeting involving experts in depressive disorders and their management was held in May 2006. Key areas in treating depression were reviewed, and the strength of evidence and clinical implications were considered. The guidelines were drawn up after extensive feedback from participants and interested parties. A literature review is provided, which identifies the quality of evidence to inform the recommendations, the strength of which are based on the level of evidence. These guidelines cover the nature and detection of depressive disorders, acute treatment with antidepressant drugs, choice of drug versus alternative treatment, practical issues in prescribing and management, next-step treatment, relapse prevention, treatment of relapse, and stopping treatment.

Original publication

DOI

10.1177/0269881107088441

Type

Journal article

Journal

J Psychopharmacol

Publication Date

06/2008

Volume

22

Pages

343 - 396

Keywords

Antidepressive Agents, Combined Modality Therapy, Complementary Therapies, Depressive Disorder, Depressive Disorder, Major, Diagnostic and Statistical Manual of Mental Disorders, Dose-Response Relationship, Drug, Drug Therapy, Combination, Electroconvulsive Therapy, Evidence-Based Medicine, Humans, Psychotherapy, Randomized Controlled Trials as Topic, Secondary Prevention, Serotonin Uptake Inhibitors, United Kingdom